INMB Stock Overview
A clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
My Notes
Capture your thoughts, links and company narrative
INmune Bio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.46 |
| 52 Week High | US$14.74 |
| 52 Week Low | US$4.32 |
| Beta | 1.79 |
| 1 Month Change | 81.94% |
| 3 Month Change | 37.23% |
| 1 Year Change | -29.97% |
| 3 Year Change | -4.73% |
| 5 Year Change | 71.60% |
| Change since IPO | 5.88% |
Recent News & Updates
Recent updates
Is INmune Bio (NASDAQ:INMB) Using Debt In A Risky Way?
Nov 03
INmune Bio: NK Cell Therapy INKmune For mCRPC Is Another Shot On Goal
Sep 30It's Unlikely That Shareholders Will Increase INmune Bio, Inc.'s (NASDAQ:INMB) Compensation By Much This Year
Jul 12Is INmune Bio (NASDAQ:INMB) Using Debt Sensibly?
Jan 19Is INmune Bio (NASDAQ:INMB) Using Debt In A Risky Way?
Sep 04Is INmune Bio (NASDAQ:INMB) Using Too Much Debt?
May 12Here's Why INmune Bio (NASDAQ:INMB) Can Manage Its Debt Despite Losing Money
Jan 16Here's Why INmune Bio (NASDAQ:INMB) Can Manage Its Debt Despite Losing Money
Jul 11INmune Bio: Possibly The Once In A Lifetime Dip
May 25INmune Bio: Speculative Biotech With 2 Solid Potential Approaches To Treating AD And Solid Tumors
Apr 05Is INmune Bio (NASDAQ:INMB) A Risky Investment?
Mar 25Shareholder Returns
| INMB | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 31.2% | 3.6% | 1.8% |
| 1Y | -30.0% | -3.7% | 24.9% |
Return vs Industry: INMB underperformed the US Biotechs industry which returned -3.7% over the past year.
Return vs Market: INMB underperformed the US Market which returned 24.9% over the past year.
Price Volatility
| INMB volatility | |
|---|---|
| INMB Average Weekly Movement | 12.7% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 18.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: INMB's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: INMB's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 14 | RJ Tesi | www.inmunebio.com |
INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company’s development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers.
INmune Bio, Inc. Fundamentals Summary
| INMB fundamental statistics | |
|---|---|
| Market cap | US$187.58m |
| Earnings (TTM) | -US$41.27m |
| Revenue (TTM) | US$42.00k |
4,466x
P/S Ratio-4.5x
P/E RatioIs INMB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| INMB income statement (TTM) | |
|---|---|
| Revenue | US$42.00k |
| Cost of Revenue | US$0 |
| Gross Profit | US$42.00k |
| Other Expenses | US$41.31m |
| Earnings | -US$41.27m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.86 |
| Gross Margin | 100.00% |
| Net Profit Margin | -98,266.67% |
| Debt/Equity Ratio | 6.4% |
How did INMB perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/26 14:02 |
| End of Day Share Price | 2025/01/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
INmune Bio, Inc. is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Molloy | Alliance Global Partners |
| Joel Beatty | Baird |
| Mayank Mamtani | B. Riley Securities, Inc. |